secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001493152-26-009309
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma doses first subjects in Phase 1b norovirus challenge study for CDI-988
--------------------------------------------------------------------------------

- First subjects dosed in Phase 1b challenge study (NCT07198139) at Emory University evaluating CDI-988 for norovirus prevention and treatment.
- CDI-988 is a direct-acting oral antiviral targeting 3CL protease; no approved norovirus treatments or vaccines exist.
- Study to enroll up to 40 healthy subjects; primary endpoint is reduction of clinical symptoms vs placebo.
- CDI-988 previously showed favorable safety in Phase 1; global norovirus economic burden estimated at $60B annually.
- FDA issued Study May Proceed Letter in Sep 2025; Emory IRB approval obtained Dec 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226009309/0001493152-26-009309-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226009309/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-009309

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer